Bartlett JM - Search Results

1

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D. Bartlett JM, et al. J Clin Oncol. 2011 Apr 20;29(12):1531-8. doi: 10.1200/JCO.2010.30.3677. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422407 Free PMC article. Clinical Trial.

2

Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen.

Langdon SP, Gabra H, Bartlett JM, Rabiaz GJ, Hawkins RA, Tesdale AL, Ritchie AA, Miller WR, Smyth JF. Langdon SP, et al. Among authors: bartlett jm. Clin Cancer Res. 1998 Sep;4(9):2245-51. Clin Cancer Res. 1998. PMID: 9748145

3

What the clinician needs from the pathologist: evidence-based reporting in breast cancer.

Going JJ, Mallon EA, Leake RE, Bartlett JM, Gusterson BA. Going JJ, et al. Among authors: bartlett jm. Eur J Cancer. 2001 Oct;37 Suppl 7:S5-17. doi: 10.1016/s0959-8049(01)80003-4. Eur J Cancer. 2001. PMID: 11888005 Review.

4

The clinical evaluation of HER-2 status: which test to use?

Bartlett J, Mallon E, Cooke T. Bartlett J, et al. J Pathol. 2003 Apr;199(4):411-7. doi: 10.1002/path.1354. J Pathol. 2003. PMID: 12635130 Review.

5

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Dowsett M, et al. J Pathol. 2003 Apr;199(4):418-23. doi: 10.1002/path.1313. J Pathol. 2003. PMID: 12635131

6

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Tovey S, et al. Among authors: bartlett jm. Clin Cancer Res. 2005 Jul 1;11(13):4835-42. doi: 10.1158/1078-0432.CCR-05-0196. Clin Cancer Res. 2005. PMID: 16000581 Free article.

7

IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.

Ainsworth R, Bartlett JM, Going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B. Ainsworth R, et al. Among authors: bartlett jm. J Clin Pathol. 2005 Oct;58(10):1086-90. doi: 10.1136/jcp.2004.021576. J Clin Pathol. 2005. PMID: 16189156 Free PMC article.

8

The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.

Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. Edwards J, et al. Among authors: bartlett jm. Clin Cancer Res. 2006 Jan 1;12(1):123-30. doi: 10.1158/1078-0432.CCR-05-1445. Clin Cancer Res. 2006. PMID: 16397033 Free article.

9

Bad expression predicts outcome in patients treated with tamoxifen.

Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM. Cannings E, et al. Among authors: bartlett jm. Breast Cancer Res Treat. 2007 Apr;102(2):173-9. doi: 10.1007/s10549-006-9323-8. Epub 2006 Sep 27. Breast Cancer Res Treat. 2007. PMID: 17004114

10

Hormonal therapy for postmenopausal breast cancer: the science of sequencing.

Miller WR, Bartlett JM, Canney P, Verrill M. Miller WR, et al. Among authors: bartlett jm. Breast Cancer Res Treat. 2007 Jun;103(2):149-60. doi: 10.1007/s10549-006-9369-7. Epub 2006 Oct 13. Breast Cancer Res Treat. 2007. PMID: 17039263 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

334 results

Search Page

Filters